Clinical Trial Update: Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Tc-99m tetrofosmin for differentiating glioma recurrence from radiation necrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Tc-99m tetrofosmin (technetium-99m tetrofosmin)

Snippet

Sponsor: Proactina S.A. | Conditions: Glioma (Diagnosis) | Phase 2 | Status: COMPLETED